ArticleFrontiers in pharmacology2026
Pharmacovigilance analysis of iodinated contrast media related respiratory adverse effects based on the FDA adverse event reporting system.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Iodinated contrast media (ICM) serve as a cornerstone in diagnostic imaging; however, the risk profile of their respiratory system adverse reactions remains inadequately characterized. This study aims to quantify and compare the respiratory system adverse reaction signals associated with four widely utilized non-ionic ICMs-iohexol, iopamidol, iopromide, and ioversol-using the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) database. Methods: We extracted data from the FAERS database spanning the first quarter of 2004 to the fourth quarter of 2024. Signal detection was performed employing the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) methodologies to identify statistically significant drug-event associations. Results: A total of 9,682 adverse event (AE) reports related to the respiratory system were analyzed, encompassing 53 distinct respiratory-related events. All four ICMs demonstrated a significant correlation with respiratory diseases. Notably, the analysis revealed that certain adverse reactions were not covered in the prescribing information. Moreover, sneezing and laryngeal edema exhibited unusually high signal intensities across all four ICMs. Conclusion: This study reveals heterogeneity in the respiratory system risk profiles among the four commonly used non-ionic ICMs. These findings suggest that clinical decision-making should incorporate the distinct risk profiles of specific ICMs, and individualized monitoring strategies should be implemented for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.